Elizabeth Weatherman Joins Insulet Board of Directors

Insulet Corporation has appointed Elizabeth “Bess” Weatherman to its Board of Directors and assigned her to the governing body’s Compensation Committee.

Weatherman is a Special Limited Partner of Warburg Pincus LLC. Since joining Warburg Pincus in 1988, she has primarily been focused on investment activities in the healthcare sector. She led the firm’s Healthcare Group from 2008 to 2015 and was previously a managing director and a member of the firm’s Executive Management Group. Warburg Pincus is a global private equity firm focused on growth investing, with more than $73 billion in assets under management and 235 portfolio companies around the world.
 
“On behalf of the Board, I am excited to welcome Bess to Insulet,” said Timothy Scannell, board chairman. “Bess brings extensive experience in healthcare and is highly regarded in the medical technology and private equity industries. Her strong leadership and strategic and governance perspectives will add tremendous value as we continue to advance our growth initiatives.”
 
Weatherman has twice been named to Forbes Midas List, recognizing her as one of the 100 most highly regarded dealmakers in the venture capital industry, and she was a recipient of the 2014 Women of Power and Influence Award from the National Organization of Women. She serves as a trustee of Stanford University and as a trustee and chair of the Investment Committee of Mount Holyoke College.
 
Weatherman currently serves as a director of Nevro Corporation, Silk Road Medical Inc., and Vapotherm Inc., all of which are publicly traded medical device companies. She earned a bachelor of arts degree from Mount Holyoke College and an M.B.A. from the Stanford Graduate School of Business.

Weatherman is filling a vacant slot left by David Lemoine, who is retiring from the board in May after six years of distinguished service. “We thank Dave for his leadership and significant contributions to Insulet,” said Scannell. “Dave has been a steadfast partner to the Board, and we wish him well in his retirement.”
 
Headquartered in Massachusetts, Insulet Corporation is the developer of the Omnipod product platform, which provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.